HPV vaccines: Global perspectives

References

• Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2(5):342-50; PMID:12044010; https://doi.org/10.1038/nrc798
   PubMed Web of Science ®Google Scholar
• Moody CA, Laimins, LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10:550-60; PMID:20592731; https://doi.org/10.1038/nrc2886
   PubMed Web of Science ®Google Scholar
• Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68:362-72; PMID:15187189; https://doi.org/10.1128/MMBR.68.2.362-372.2004
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29(32):4294-301; PMID:21969503; https://doi.org/10.1200/JCO.2011.36.4596
   PubMed Web of Science ®Google Scholar
• Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113(10):3036-46; PMID:18980286; https://doi.org/10.1002/cncr.23764
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garlan SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30(5):F123-38; PMID:23199956; https://doi.org/10.1016/j.vaccine.2012.04.108
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A randomized, double-blind, Phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls. Pediatr Infect Dis J 2015; 34(9):992-8; PMID:26090572; https://doi.org/10.1097/INF.0000000000000773
   PubMed Web of Science ®Google Scholar
• Schiller JT, Muller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 2015; 16(5):e217-25; PMID:25943066; https://doi.org/10.1016/S1470-2045(14)71179-9
   PubMed Web of Science ®Google Scholar
• Monie A, Hung CF, Roden R, Wu TC. CervarixTM: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008; 2(1):107-13
   Google Scholar
• Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321(2):205-16; PMID:15051381; https://doi.org/10.1016/j.virol.2003.12.027
   PubMed Web of Science ®Google Scholar
• Chen XS, Casini G, Harrison SC, Garcea RL. Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1. J Mol Biol 2001; 307(1):173-82; PMID:11243812; https://doi.org/10.1006/jmbi.2000.4464
   PubMed Web of Science ®Google Scholar
• Gupta G, Glueck R, Rishi N. Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles. Biologicals in press; PMID:28012703; https://doi.org/10.1016/j.biologicals.2016.12.002
   PubMed Web of Science ®Google Scholar
• Hanumantha Rao N, Baji Babu P, Rajendra L, Sriraman R, Pang YY, Schiller JT, Srinivasan VA. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine 2011; 29(43):7326-34; PMID:21803095; https://doi.org/10.1016/j.vaccine.2011.07.071
   PubMed Web of Science ®Google Scholar
• Li W, He X, Guo X, Zhang Z, Zhang B. Optimized expression of the L1 protein of human papillomavirus in Hansenula polymorpha. Shengwu Gongcheng Xuebao 2009; 25(10):1516-23
   Google Scholar
• Rybicki EP, Williamson AL, Meyers A, Hitzeroth II. Vaccine farming in Cape Town. Hum Vaccin 2011; 7(3):339-48; PMID:21358269; https://doi.org/10.4161/hv.7.3.14263
   PubMed Web of Science ®Google Scholar
• Cantarella G, Liniger M, Zuniga A, Schiller JT, Billeter M, Naim HY, Glueck R. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009; 27(25–26):3385-90; PMID:19200837; https://doi.org/10.1016/j.vaccine.2009.01.061
   PubMed Web of Science ®Google Scholar
• Kuck D, Lau T, Leuchs B, Kern A, Müller M, Gissmann L, Kleinschmidt JA. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 2006; 80(6):2621-30; PMID:16501072; https://doi.org/10.1128/JVI.80.6.2621-2630.2006
   PubMed Web of Science ®Google Scholar
• Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, Ponci F, Nardelli-Haefliger D. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007; 14(10):1285-95; PMID:17687110; https://doi.org/10.1128/CVI.00164-07
   PubMed Web of Science ®Google Scholar
• Gupta G, Viviana G, Rishi N, Glueck R. Immunogenicity of next generation HPV vaccines in non-human primates: Measles vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine. Vaccine 2016; 34:4724-31; PMID:27523740; https://doi.org/10.1016/j.vaccine.2016.07.051
   PubMed Web of Science ®Google Scholar
• Thönes N, Herreiner A, Schädlich L, Piuko K, Müller MA. Direct comparison of human papillomavirus type 16L1 particles reveals a lower immunogenicity of capsomers than virus like particles with respect to the induced antibody response. J Virol 2008; 82:5472-85; PMID:18385253; https://doi.org/10.1128/JVI.02482-07
   PubMed Web of Science ®Google Scholar
• Schädlich L, Senger T, Gerlach B, Mücke N, Klein C, Bravo IG, Müller M, Gissmann L. Analysis of modified HPV 16L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 2009; 83:7690-705; PMID:19457985; https://doi.org/10.1128/JVI.02588-08
   PubMed Web of Science ®Google Scholar
• Davies L. Human papillomavirus vaccines— a review of advances in the development of HPV vaccines. HIV Treatment Bulletin 2005; 6(7); 1-72
   Google Scholar
• Ling M, Kanayama M, Roden R, Wu TC. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed Sci 2000; 7:341-56; PMID:10971133; https://doi.org/10.1007/BF02255810
   PubMed Web of Science ®Google Scholar
• Tomson TT, Roden RB, Wu TC. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Invest Drugs 2004; 5(12):1247-61
   PubMedGoogle Scholar
• Karanam B, Jagu S, Huh WK, Roden RB. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009; 87(4):287-99; PMID:19421199; https://doi.org/10.1038/icb.2009.13
   PubMed Web of Science ®Google Scholar
• Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, Christensen ND, Roden RB. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007; 81(21):11585-92; PMID:17715230; https://doi.org/10.1128/JVI.01577-07
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005; 337(2):365-72; PMID:15885736; https://doi.org/10.1016/j.virol.2005.04.011
   PubMed Web of Science ®Google Scholar
• Roden RB, Yutzy WH 4th, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant: cross-neutralizing epitopes. Virology 2000; 270(2):254-7; PMID:10792983; https://doi.org/10.1006/viro.2000.0272
   PubMed Web of Science ®Google Scholar
• Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Müller M, Ottonello S. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2(20–38) peptide displayed on bacterial thioredoxin. Vaccine 2009; 27(13):1949-56; PMID:19368776; https://doi.org/10.1016/j.vaccine.2009.01.102
   PubMed Web of Science ®Google Scholar
• Nakao S, Mori S, Kondo K, Matsumoto K, Yoshikawa H, Kanda T. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology 2012; 434(1):110; PMID:23051711; https://doi.org/10.1016/j.virol.2012.09.006
   PubMed Web of Science ®Google Scholar
• Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB. A protective and broadly cross-neutralizing epitope of humanpapillomavirus L2. J Virol 2007; 81(24):13927-31; PMID:17928339; https://doi.org/10.1128/JVI.00936-07
   PubMed Web of Science ®Google Scholar
• Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011; 6(8):e23310; PMID:21858066; https://doi.org/10.1371/journal.pone.0023310
   PubMed Web of Science ®Google Scholar
• Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 2012; 7(11):e49751; PMID:23185426; https://doi.org/10.1371/journal.pone.0049751
   PubMed Web of Science ®Google Scholar
• Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009; 83(19):10085-95; PMID:19640991; https://doi.org/10.1128/JVI.01088-09
   PubMed Web of Science ®Google Scholar
• Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RB, Kirnbauer R. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 2013; 133(12):2706-13; PMID:23752042; https://doi.org/10.1038/jid.2013.253
   PubMed Web of Science ®Google Scholar
• Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Nat Cancer Inst 2009; 101(11):782-92; PMID:19470949; https://doi.org/10.1093/jnci/djp106
   PubMed Web of Science ®Google Scholar
• Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, Roden RB. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 2013; 8(1):e55538; PMID:23383218; https://doi.org/10.1371/journal.pone.0055538
   PubMed Web of Science ®Google Scholar
• Seitz H, Canali E, Ribeiro-Müller L, Pàlfi A, Bolchi A, Tommasino M, Ottonello S, Müller MA. Three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. Vaccine 2014; 32(22):2610-7; PMID:24662712; https://doi.org/10.1016/j.vaccine.2014.03.033
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Newsroom home.Press materials. CDC news room releases. 2016 Oct 19 [accessed 2017 Jan 13]. https://www.cdc.gov/media/releases/2016/p1020-hpv-shots.html
   Google Scholar
• Doorbar J. Model systems of human papillomavirus-associated disease. J Pathol 2016; 238(2):166-79; PMID:26456009; https://doi.org/10.1002/path.4656
   PubMed Web of Science ®Google Scholar
• Yang A, Jeang J, Cheng K, Cheng T, Yang B, Wu TC, Hung CF. Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 2016; 15(8):989-1007; PMID:26901118; https://doi.org/10.1586/14760584.2016.1157477
   PubMed Web of Science ®Google Scholar
• Ma B, Maraj B, Tran NP, Knoff J, Chen A, Alvarez RD, Hung CF, Wu TC. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012; 17(4):469-92; PMID:23163511; https://doi.org/10.1517/14728214.2012.744393
   PubMed Web of Science ®Google Scholar
• Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci 2016; 23:75; PMID:27809842; https://doi.org/10.1186/s12929-016-0293-9
   PubMed Web of Science ®Google Scholar